Recent Updates
Recently added Catalysts
NKTR Positive Sentiment

Nektar Management to Present at the TD Cowen 44th Annual Health Care Conference Nektar Therapeutics (Nasdaq: NKTR) management is scheduled to present at the upcoming TD Cowen 44th Annual Health Care Conference in Boston on...

Tuesday, February 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Nektar Therapeutics is set to present at the TD Cowen 44th Annual Health Care Conference in Boston on March 5, 2024. The event will begin at 2:10 p.m. Eastern Time and will include a Q&A session accessible via webcast. This presentation highlights Nektar's ongoing commitment to engaging with investors and providing updates on its development programs.
Price reaction · baseline $10.05 (2024-02-26 close) · hit after-hours · clean, no other NKTR news in the window
day 0 close
+11.9%
day 1
+7.5%
day 3 · peak
+16.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Nektar will present at a prestigious health care conference
  • The presentation will include a Q&A session, allowing for audience interaction
  • The company has a robust R&D pipeline in immunology and oncology

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+186%
120-day peak, hindsight
Typical move
10.2%
average across 4 past catalysts
Cash runway
~40 mo
Minimal dilution risk
Lead asset
Rezpegaldesleukin
Phase 3 · Moderate-to-Severe Atopic Dermatitis

Full Press Release Details

SAN FRANCISCO , Feb. 27, 2024 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR ) management is scheduled to present at the upcoming TD Cowen 44 th Annual Health Care Conference in Boston on Tuesday, March 5, 2024 at 2:10 p.m. Eastern Time .
The presentation and Q&A session will be accessible via a webcast through a link posted on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events . This webcast will be available for replay until April 5, 2024 .
About Nektar Therapeutics Nektar Therapeutics is a biopharmaceutical company with a robust, wholly owned R&D pipeline of investigational medicines in immunology and oncology as well as a portfolio of approved partnered medicines. Nektar is headquartered in San Francisco, California , with additional operations in Huntsville, Alabama . Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com .

Frequently Asked Questions

When is Nektar Therapeutics presenting at the conference?

Nektar Therapeutics will present on March 5, 2024, at 2:10 p.m. ET.

Where can I watch Nektar's presentation and Q&A?

The presentation will be available via webcast on Nektar's Investor Events page.

How long will the webcast be available for replay?

The webcast will be available for replay until April 5, 2024.

What areas does Nektar Therapeutics focus on?

Nektar specializes in immunology and oncology, with a strong R&D pipeline.

Where is Nektar Therapeutics headquartered?

Nektar Therapeutics is headquartered in San Francisco, California.

ShareAdd on Google
Tags: NKTR Viatris Investor Conferences Healthcare Nektar Therapeutics TD Cowen Conference health care conference biopharmaceuticals
Last updated: Feb 27, 2024

Biotech snapshot

Cash runway
$1023M liquidity · $25M/mo burn
~40 mo
Minimal dilution risk
Lead asset
RezpegaldesleukinPhase 3
Moderate-to-Severe Atopic Dermatitis →

Catalyst track record

+186%
best trade around NKTR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for NKTR.

See every catalyst's timing & PoA →